Axel Wester

MD, PhD. Assistant professor. @karolinskainst

[Maurice Michel @MMichel_MD]

Deeply honored and humbled to have received the investigator award @Apasl2024 in Kyoto 🇯🇵! A huge thanks to @schattenbergJ and the excellent collaboration with @HannesHagstrom and @wester_axel! Many thanks to the great host! @APASLnews

[Robert Fontana @RobertFontanaMD]

Important retrospective study that suggest that GLP-1 agonists may have benefit in improving hepatic morbidity and mortality @JasmohanBajaj @MichiganLiver @LiverFellow

[Gut Journal @Gut_BMJ]

Read the paper by @wester_axel et al on

"Glucagon-like peptide-1 receptor agonists + risk of major adverse liver outcomes in patients with chronic liver disease + type 2 diabetes" via

https://t.co/HxpOjUPeKK

@hanneshagstrom @yingshang1 @_tony_matthews @karolinskainst #GLP1

[Scott Isaacs @scottisaacsmd]

GLP-1 medications and the risk of major adverse liver outcomes #MALO in patients with chronic liver disease and type 2 #diabetes.
https://t.co/eHcQceN7mN

[SAMI ALMOMEN @SALMOMEN]

Glucagon-like peptide-1 receptor agonists and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes | Gut https://t.co/F45Slk6iVV

[Gut Journal @Gut_BMJ]

Read the paper by @wester_axel et al on

"Glucagon-like peptide-1 receptor agonists + risk of major adverse liver outcomes in patients with chronic liver disease + type 2 diabetes" via

https://t.co/HxpOjUPeKK

@hanneshagstrom @yingshang1 @_tony_matthews @karolinskainst #GLP1

[Karolinska Institutet @karolinskainst]

#GLP1 agonists are associated with a reduced risk of developing cirrhosis and liver cancer in people with type 2 #diabetes and chronic liver disease, finds a new KI study by @wester_axel and @hanneshagstrom published in @Gut_BMJ. #Hepatology https://t.co/ZmnD79mnXc

[Liver International @LiverInt]

1/2
📚 Patients with non-alcoholic fatty liver disease (NAFLD) have a ⬆️ rate and risk of severe infections compared to the general population

👀 The risk was independent of other metabolic syndrome components

🔓 https://t.co/ilXR8zjZA5

#livertwitter

[Elliot Tapper @ebtapper]

Alcohol-related #cirrhosis cuts 14 years off the life expectancy of men and 16 for women

https://t.co/qZkMyrL7bg #livertwitter

What @HannesHagstrom is doing with Swedish data is so important

[Alessio Gerussi @AlessioGerussi]

Data from @karolinskainst show that PBC patients have higher risk of cancer, mostly driven by HCC but with a signal on lymphoma that deserves attention @EASLedu @ERN_RARE_LIVER #LiverTwitter #ilc2023

[Elliot Tapper @ebtapper]

A huge unmet need for quality improvement in #cirrhosis care is in the transition from hospital to home; aftercare following decompensation, secondary prophylaxis

💪work from @HannesHagstrom @yingshing @wester_axel & Linnea Widman #livertwitter https://t.co/VE7YEoApn2

[Gastroenterology Advisor @Gastro_Advisor]

Patients with alcohol-related cirrhosis have an almost 4-fold increased fracture rate as well as an increased 30-day and 1-year postfracture mortality rate compared with the general population. Study in @AGA_CGH. @wester_axel @HannesHagstrom #GItwitter

https://t.co/AnsVD9CGcG

[JIM - Journal of Internal Medicine @JInternMed]

In a Swedish nationwide population-based cohort study, the risk of fractures in NAFLD was similar to the general population. This suggests that broad surveillance of fracture risk factors in NAFLD is not motivated.

✏️@hanneshagstrom @wester_axel

📰https://t.co/J1KQFGine9

[JAHA @JAHA_AHA]

Limited usefulness of PRECISE-DAPT for high bleeding risk patients with myocardial infarction in SWEDEHEART. https://t.co/k0cFOt1WWO @wester_axel @lunduniversity

[Paperbirds_Oncology @PaperbirdsO]

New article: Validation of the 4-Item PRECISE-DAPT Score: A SWEDEHEART Study https://t.co/dMn3x0BJfL #kidneycancer #oncology

[Paramedic papers @ParamedicPapers]

Validation of the 4-Item PRECISE-DAPT Score: A SWEDEHEART Study https://t.co/i7a6kZ8mOJ

[JAHA @JAHA_AHA]

#Anemia constitutes a high‐risk feature in patients with #acute #coronary #syndromes https://t.co/yYFGgSHnQL #AHAJournals

[Consejo Español RCP @ConsEspRCP]

Coronariografía tras PCR en SCASEST demuestra lesiones coronarias severas en 43,9% pero no produce beneficio su realización temprana. https://t.co/7zTfgouscq